UBS Group
ENTL

UBS Group’s Entellus Medical, Inc. Common Stock ENTL Stock Holding History

UBS Group’s Portfolio ENTL Stock Details ENTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,035
Closed -$74K – 8505
2017
Q4 		$74K Buy
3,035
+2,129
+235% +$40.9K ﹤0.01% 5570
2017
Q3 		$16K Sell
906
-3,694
-80% -$64K ﹤0.01% 6629
2017
Q2 		$76K Buy
4,600
+2,782
+153% +$38.7K ﹤0.01% 5362
2017
Q1 		$25K Buy
1,818
+84
+5% +$1.35K ﹤0.01% 6005
2016
Q4 		$33K Buy
1,734
+506
+41% +$9.71K ﹤0.01% 6175
2016
Q3 		$27K Buy
1,228
+628
+105% +$11.8K ﹤0.01% 6054
2016
Q2 		$11K Sell
600
-425
-41% -$7.32K ﹤0.01% 6749
2016
Q1 		$19K Sell
1,025
-75
-7% -$1.21K ﹤0.01% 6265
2015
Q4 		$19K Hold
1,100
– – ﹤0.01% 6833
2015
Q3 		$20K Hold
1,100
– – ﹤0.01% 6715
2015
Q2 		$28K Buy
1,100
+600
+120% +$15.2K ﹤0.01% 6573
2015
Q1 		$11K Buy
+500
New +$10.8K ﹤0.01% 7598

UBS Group's ENTL Position: Q1 2018 in Review

UBS Group sold out of Entellus Medical, Inc. Common Stock (ENTL) in Q1 2018, closing a stake of 3,035 shares — an estimated $74K sold.

UBS Group first reported a position in ENTL in Q1 2015 and held it in 12 quarters. The position peaked at $76K in Q2 2017. 0 funds tracked by Wall St. Rank hold ENTL as of Q1 2018.

  • UBS Group reported no remaining Entellus Medical, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • UBS Group sold 3,035 Entellus Medical, Inc. Common Stock shares in Q1 2018, an estimated $74K.
  • UBS Group first reported a position in Entellus Medical, Inc. Common Stock in Q1 2015 and held it in 12 quarters.
  • UBS Group's Entellus Medical, Inc. Common Stock position peaked at $76K in Q2 2017.
  • 0 funds tracked by Wall St. Rank held Entellus Medical, Inc. Common Stock as of Q1 2018.

Based on UBS Group's 13F filing for Q1 2018, filed 15 May 2018.